TESARO Announces U.S. FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy
October 25, 2017 19:15 ET | TESARO, Inc.
VARUBI injectable emulsion features a ready-to-use, single-dose vial for intravenous administrationAvailability of new formulation offers healthcare providers the flexibility to choose oral or IV...
TESARO® logo_RGB_small.png
TESARO Provides Business and Pipeline Update at ASCO Investor Briefing
June 03, 2017 18:30 ET | TESARO, Inc.
Initial TOPACIO data for niraparib plus KEYTRUDA® is indicative of potentially synergistic anti-tumor activity in platinum-resistant ovarian cancerPhase 1 results for TSR-042 show anti-PD-1...
TESARO® logo_RGB_small.png
TESARO Announces Approval of VARUBY® (Oral Rolapitant Tablets) by European Commission
April 26, 2017 08:30 ET | TESARO, Inc.
VARUBY provides protection for delayed chemotherapy-induced nausea and vomiting (CINV) with a single dose as part of an antiemetic regimenUp to 50% of patients undergoing highly or moderately...
TESARO® logo_RGB_small.png
TESARO Announces Fourth-Quarter 2016 Operating Results
February 28, 2017 16:05 ET | TESARO, Inc.
Niraparib NDA under review by FDA; pre-launch preparations for planned commercial launch well underwayExpanded access program (EAP) for niraparib open in U.S.; European EAP expected to open 1H...
TESARO® logo_RGB_small.png
TESARO Receives Positive CHMP Opinion for VARUBY®
February 27, 2017 02:00 ET | TESARO, Inc.
WALTHAM, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the European Medicines Agency’s (EMA) Committee for...
TESARO® logo_RGB_small.png
TESARO Outlines Business Priorities and Strategic Outlook for 2016
January 11, 2016 08:15 ET | TESARO, Inc.
U.S. commercial launch of VARUBI™ (oral rolapitant) well underwayData from niraparib NOVA and QUADRA registration trials expected in Q2 2016 Niraparib New Drug Application (NDA) submission planned...